Down 7%: Clovis' ASCO News

Clovis Oncology's  (NASDAQ: CLVS  )  lung cancer drug CO-1686 was in the spotlight at ASCO today, and, while the drug seemed to be potentially more effective than AstraZeneca's  (NYSE: AZN  ) competitor AZD9291, the stock still dropped.

In a phase 1/2 trial, CO-1686 caused high blood sugar in 22% of patients, according to Clovis, and CEO Pat Mahaffay reportedly commented that a few patients had to receive insulin injections to handle their hyperglycemia.

In this video, from Monday's Market Checkup, the Motley Fool's health care-focused investing show, analysts Michael Douglass and David Williamson discuss the side effects and what this could mean for Clovis moving forward.

Even if the next batch of data is much better, Clovis could have serious trouble keeping up with this top stock.
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2979999, ~/Articles/ArticleHandler.aspx, 7/26/2014 3:52:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement